China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug [Yahoo! Finance]
Scholar Rock Holding Corporation (SRRK)
Last scholar rock holding corporation earnings: 11/12 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
WHY IT MATTERS Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion in revenue by the next decade. Last year, the company spent about $2 billion to acquire Versanis' drug that acts directly on fat cells, without prompting lean mass loss. Several other drugmakers including Regeneron and Scholar Rock are testing treatments that could help preserve muscle, which is often lost when patients lose weight through lifestyle changes, bariatric surgery or the use of GLP-1 treatments such as Lilly's Zepbound and Novo Nordisk's Wegovy. CONTEXT The collaboration will accelerate the development of Laekna's experimental drug, LAE102, which belongs to a class of drugs that play a key role in muscle regeneration as well as the breakdown and storage of fat for energy. Lilly will fund the development of the drug and share its resources and expertise, but Laekna will retain the global rights for the drug and plans to adva
Show less
Read more
Impact Snapshot
Event Time:
SRRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRRK alerts
High impacting Scholar Rock Holding Corporation news events
Weekly update
A roundup of the hottest topics
SRRK
News
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025Business Wire
- Scholar Rock Holding Co. (NASDAQ: SRRK) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $47.00 price target on the stock.MarketBeat
- Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)Business Wire
- Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership TransitionBusiness Wire
SRRK
Earnings
- 11/12/24 - Miss
SRRK
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form SCHEDULE
- 2/12/25 - Form SCHEDULE
- SRRK's page on the SEC website